Osteosarcoma
The commonest bone cancer in teenagers; relapsed and metastatic disease remain hard to treat.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 40 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for osteosarcoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 15 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | genetic literature | Literature | Animal models | Pathways | Clinical | RNA expr. |
|---|---|---|---|---|---|---|---|---|---|
| TP53Peds RMTL tumor protein p53 | 0.79 | 0.89 | 0.84 | ||||||
| CHEK2 checkpoint kinase 2 | 0.74 | 0.93 | 0.64 | ||||||
| RB1 RB transcriptional corepressor 1 | 0.72 | 0.86 | 0.73 | ||||||
| RECQL4 RecQ like helicase 4 | 0.58 | 0.56 | 0.46 | ||||||
| LPAR6 lysophosphatidic acid receptor 6 | 0.52 | 0.84 | – | ||||||
| SQSTM1 sequestosome 1 | 0.50 | – | – | ||||||
| ATRXPeds RMTL ATRX chromatin remodeler | 0.48 | – | 0.62 | ||||||
| CDKN2A cyclin dependent kinase inhibitor 2A | 0.48 | 0.19 | 0.61 | ||||||
| IDH2Peds RMTL isocitrate dehydrogenase (NADP(+)) 2 | 0.46 | – | 0.59 | ||||||
| SMARCAL1 SNF2 related chromatin remodeling annealing helicase 1 | 0.45 | 0.72 | – | ||||||
| ZFHX3 zinc finger homeobox 3 | 0.44 | – | 0.58 | ||||||
| NF1 neurofibromin 1 | 0.43 | – | 0.60 | ||||||
| IDH1Peds RMTL isocitrate dehydrogenase (NADP(+)) 1 | 0.43 | – | 0.55 | ||||||
| TOP2A DNA topoisomerase II alpha | 0.42 | – | – | ||||||
| PTCH1 patched 1 | 0.42 | – | 0.55 | ||||||
| GNAS GNAS complex locus | 0.42 | – | 0.65 | ||||||
| POLE DNA polymerase epsilon, catalytic subunit | 0.41 | – | 0.53 | ||||||
| DHFR dihydrofolate reductase | 0.41 | – | – | ||||||
| FOXP1 forkhead box P1 | 0.41 | – | 0.64 | ||||||
| KMT2C lysine methyltransferase 2C | 0.40 | – | 0.64 | ||||||
| NOD2 nucleotide binding oligomerization domain containing 2 | 0.40 | – | – | ||||||
| KDR kinase insert domain receptor | 0.40 | – | 0.53 | ||||||
| FLI1 Fli-1 proto-oncogene, ETS transcription factor | 0.39 | – | 0.61 | ||||||
| TOP2B DNA topoisomerase II beta | 0.39 | – | – | ||||||
| LRP1B LDL receptor related protein 1B | 0.39 | – | 0.51 | ||||||
| EGFRPeds RMTL epidermal growth factor receptor | 0.38 | – | 0.57 | ||||||
| MYCPeds RMTL MYC proto-oncogene, bHLH transcription factor | 0.38 | – | 0.57 | ||||||
| PTENPeds RMTL phosphatase and tensin homolog | 0.38 | – | 0.57 | ||||||
| BRAFPeds RMTL B-Raf proto-oncogene, serine/threonine kinase | 0.38 | – | 0.57 | ||||||
| NOTCH1Peds RMTL notch receptor 1 | 0.37 | – | 0.57 | ||||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.37 | – | 0.57 | ||||||
| ARID1A AT-rich interaction domain 1A | 0.37 | – | 0.48 | ||||||
| SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4 | 0.37 | – | 0.60 | ||||||
| ROS1Peds RMTL ROS proto-oncogene 1, receptor tyrosine kinase | 0.37 | – | 0.60 | ||||||
| H3-3A H3.3 histone A | 0.37 | – | 0.60 | ||||||
| AXIN2 axin 2 | 0.37 | – | 0.57 | ||||||
| SETD2 SET domain containing 2, histone lysine methyltransferase | 0.37 | – | 0.48 | ||||||
| SMAD2 SMAD family member 2 | 0.36 | – | 0.57 | ||||||
| METPeds RMTL MET proto-oncogene, receptor tyrosine kinase | 0.36 | – | 0.42 | ||||||
| FLT3Peds RMTL fms related receptor tyrosine kinase 3 | 0.35 | – | 0.53 | ||||||
| MAP2K1Peds RMTL mitogen-activated protein kinase kinase 1 | 0.35 | – | 0.53 | ||||||
| ATRPeds RMTL ATR checkpoint kinase | 0.35 | – | 0.53 | ||||||
| NTRK2 neurotrophic receptor tyrosine kinase 2 | 0.35 | – | 0.57 | ||||||
| RRM2 ribonucleotide reductase regulatory subunit M2 | 0.35 | – | – | ||||||
| AR androgen receptor | 0.35 | – | 0.53 | ||||||
| DNMT3A DNA methyltransferase 3 alpha | 0.35 | – | 0.53 | ||||||
| ERBB4 erb-b2 receptor tyrosine kinase 4 | 0.35 | – | 0.53 | ||||||
| NTRK3 neurotrophic receptor tyrosine kinase 3 | 0.35 | – | 0.57 | ||||||
| SOCS1 suppressor of cytokine signaling 1 | 0.35 | – | 0.53 | ||||||
| KMT2D lysine methyltransferase 2D | 0.35 | – | 0.57 |
1 biomarker in Osteosarcoma has validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Osteosarcoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 5 accepted items exist; the first 5 were read. This is the published evidence, not treatment advice.
- ERCC2 K751Q level B